EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Glucose metabolic reprogramming in systemic lupus erythematosus and lupus nephritis: theoretical foundations and therapeutic implications

Hongyong Su, Le Zhang, Qiaofei Zhang, Lijing Liu, Liping Zhai, Xiaocui Chen, Chen Yang, Ning An, Hua-Feng Liu

Frontiers in Immunology · 02.04.2026 · 17

DOI: 10.3389/fimmu.2026.1799232 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Immunology, online erschienen am 02.04.2026. Verfasst von Hongyong Su und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, National Clinical Key Specialty Construction Program (2023), Institute of Nephrology, Guangdong Provincial Key Laboratory o…. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Glucose, Lupus Nephritis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 150 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lupus nephritis (LN) represents the most severe and frequent complication of systemic lupus erythematosus (SLE), yet its treatment remains a significant unmet clinical need. Recent advances in immunometabolism have revealed that glucose metabolic reprogramming—including shifts in glycolysis, the pentose phosphate pathway (PPP), and the tricarboxylic acid (TCA) cycle—plays a central role in driving pathogenic immune cell activation in SLE. However, a critical gap persists in understanding how these metabolic alterations specifically operate within the renal microenvironment to promote immune cell infiltration and intrinsic kidney cell injury in LN. This review synthesizes current evidence on the molecular mechanisms linking glucose metabolism to immune dysfunction in innate immune cells including monocytes/macrophages, neutrophils and DCs and adaptive immune cells including T cells, B cells and renal resident cells. We further discuss therapeutic strategies targeting metabolic pathways, including repurposed drugs (metformin, hydroxychloroquine, rapamycin), preclinical small molecules (PKM2, PFKFB3, LDHA, GLUT1 inhibitors), and combination therapies with biologics. Safety considerations, particularly the sensitivity of regulatory T cells (Tregs) to glycolysis inhibition, underscore the need for dose optimization. Finally, we highlight future directions, including real-time metabolic imaging, personalized glycolysis scoring, and spatiotemporal metabolic epigenetic models, which hold promise for advancing precision medicine in LN.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicGlucoseLupus NephritisHumansMetabolic ReprogrammingAnimalsGlycolysis

Stichwörter der Autor:innen

glucoseglycolysisimmune cellsmetabolic reprogrammingsystemic lupus erythematosus

Substanzen

Glucose

Autor:innen und Institutionen

  • Department of Nephrology, National Clinical Key Specialty Construction Program (2023), Institute of Nephrology, Guangdong Provincial Key Laboratory of Autophagy and Major Chronic Noncommunicable Diseases, Key Laboratory…
  • Faculty of Chinese Medicine, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macao, Macao SAR, China.
  • Guangdong Medical University, Zhanjiang, China.

Zitieren

APA

Su, H., Zhang, L., Zhang, Q., Liu, L., Zhai, L., Chen, X., Yang, C., An, N., & Liu, H. F. (2026). Glucose metabolic reprogramming in systemic lupus erythematosus and lupus nephritis: theoretical foundations and therapeutic implications. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1799232

Vancouver

Su H, Zhang L, Zhang Q, Liu L, Zhai L, Chen X, et al. Glucose metabolic reprogramming in systemic lupus erythematosus and lupus nephritis: theoretical foundations and therapeutic implications. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1799232

BibTeX
@article{Su2026,
  author = {Su, Hongyong and Zhang, Le and Zhang, Qiaofei and Liu, Lijing and Zhai, Liping and Chen, Xiaocui and Yang, Chen and An, Ning and Liu, Hua-Feng},
  title = {Glucose metabolic reprogramming in systemic lupus erythematosus and lupus nephritis: theoretical foundations and therapeutic implications},
  journal = {Frontiers in Immunology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fimmu.2026.1799232}
}
Kostenlos starten →